CTLA4 and cancer: The development of therapeutic monoclonal antibodies that block co-inhibitory receptors on T cells, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1), has shown exceptional clinical benefit in cancer patients and is seen as a crucial breakthrough in the cancer immunotherapy field (1).